脑卒中短暂性中动脉闭塞模型
2023年8月11日
3.5K 次观看
该方案描述了通过大脑中动脉腔内闭塞在小鼠中短暂性局灶性脑缺血的模型。此外，还显示了使用磁共振成像和行为测试的结果评估示例。
大脑中动脉闭塞模型被广泛用于模拟小鼠缺血性脑卒中。该模型允许研究缺血性损伤的时间进展，评估神经保护剂的有效性，并探索特定基因和通路在中风病理学中的作用，最终目的是寻找新的潜在治疗方法。MRI等神经成像技术的实施可以更好地诊断，改善结果评估，并减少每项研究中所需的动物数量。
该协议对诱导短暂性大脑中动脉闭塞的最常用技术进行了清晰而详细的解释。此外，它通过引入闭塞期间麻醉退出的精确修改来实现该技术，从而减少了长时间麻醉时间的不利影响。
查看完整文字稿并访问数千部科学视频
概述
本研究提出了一种使用中动脉闭塞法在小鼠中诱导短暂局灶性脑缺血的协议。通过磁共振成像和行为评估来评估该方法，以了解缺血性损伤的进展及潜在神经保护剂的有效性。
关键研究组成部分
科学领域
- 神经科学
- 中风研究
- 神经影像学
背景
- 中动脉闭塞模型模拟小鼠的缺血性中风。
- 该模型分析缺血性损伤的时间进展。
- 行为测试评估缺血性损伤后的运动缺陷。
- 神经影像技术有助于结果评估并减少动物使用。
研究目的
- 提供诱导短暂中动脉闭塞的详细协议。
- 评估神经保护剂在缺血模型中的有效性。
- 探索与中风病理相关的特定基因和通路。
使用的方法
- 研究利用小鼠模型诱导短暂局灶性脑缺血。
- 涉及中动脉闭塞的手术程序，同时监测脑血流。
- 使用MRI和行为测试在闭塞后不同时间点评估结果。
- 详细包括麻醉管理和手术协调，以最大程度地减少压力和并发症。
主要结果
- MRI测量显示闭塞后约两天内病变进展。
- 行为评估显示抓力减弱和向伤害部位的定向转向偏向。
- 该方法成功展示了缺血机制和潜在的治疗干预。
结论
- 该协议能够全面评估缺血性损伤和治疗的有效性。
- 研究结果增强了对脑缺血机制的理解，并支持未来的治疗开发。
- 总体而言，这项工作为中风和神经保护策略的改进模型做出了贡献。
常见问题
使用中动脉闭塞模型的优点是什么？
该模型能够紧密模拟人类缺血性中风，允许评估损伤进展的时间和治疗效果。
如何进行中动脉闭塞？
手术程序包括闭塞特定动脉并监测脑血流以在目标脑区诱导缺血。
从这项研究中获得哪些类型的数据？
数据包括MRI的成像结果、行为评估以及闭塞期间和闭塞后的血流特征评估。
如何将这种方法应用于其他研究？
可以修改该协议以评估响应缺血条件的各种遗传或药理学干预措施。
这种方法有哪些局限性？
个体小鼠之间的反应差异和手术精度的潜在并发症可能影响重复性。
Executive Industry Relevance
The transient middle cerebral artery occlusion (MCAO) model in mice provides a robust, reproducible platform for evaluating ischemic stroke mechanisms and candidate neuroprotective agents. This model enables quantitative assessment of lesion progression and functional outcomes, supporting predictive confidence in early-stage CNS therapeutic discovery. Its integration of neuroimaging and behavioral endpoints enhances translational continuity from preclinical research to clinical hypothesis generation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of gene and pathway involvement in stroke pathology using genetically modified mice.
- Supports biological de-risking by clarifying mechanistic links between molecular targets and ischemic outcomes.
- Facilitates predictive confidence in target selection for neuroprotective strategies.
Screening & Assay Development
- Provides a validated in vivo system for screening neuroprotective compounds under controlled ischemic conditions.
- Standardizes outcome measurement through MRI and behavioral assays, ensuring reproducibility across studies.
- Generates quantitative data on lesion volume and functional deficits for reliable compound evaluation.
Translational & Preclinical Research
- Aligns preclinical endpoints with clinical imaging and behavioral assessments, supporting translational biomarker development.
- Enables longitudinal tracking of lesion evolution and therapeutic response post-reperfusion.
- Reduces animal use through advanced neuroimaging, optimizing resource allocation in preclinical programs.
Pipeline & Workflow Integration
The MCAO model bridges early discovery, lead identification, and preclinical validation phases in CNS drug development pipelines.
- Discovery Biology: Supports hypothesis testing on gene function and pathway relevance in ischemic injury.
- Screening: Delivers reproducible, quantitative readouts for compound efficacy in a disease-relevant system.
- Analytics: Integrates MRI and behavioral data for robust statistical comparison of experimental groups.
- Translational Research: Provides continuity between preclinical findings and clinical imaging endpoints.
- Enterprise Reuse: Offers a standardized, scalable platform adaptable to diverse genetic and pharmacological studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in CNS target validation.
- Operational Value: Enhances reproducibility and standardization through integrated imaging and behavioral protocols.
- Strategic Value: Informs go/no-go decisions and prioritizes assets with translational potential.
- Portfolio Impact: Supports risk-adjusted advancement and resource allocation across neurotherapeutic programs.
Implementation Considerations
- Requires expertise in microsurgical techniques and neuroimaging analysis.
- Demands access to MRI infrastructure and behavioral testing platforms.
- Necessitates rigorous cross-team standardization of surgical and analytical procedures.
- Adaptable to various genetic backgrounds and pharmacological interventions in mice.
- Potential variability in surgical outcomes requires careful quality control and statistical planning.
Biopharma FAQs
Why does null hypothesis testing matter for MCAO target validation?
Null hypothesis testing in the MCAO model enables objective evaluation of whether genetic or pharmacological interventions significantly alter lesion size or behavioral outcomes. This statistical rigor is essential for confirming target relevance and reducing false positives in early discovery. Reliable hypothesis testing supports confident progression of neuroprotective candidates.
How does independent variable isolation fit MCAO-based discovery?
Isolating variables such as gene knockout or compound administration in the MCAO model allows clear attribution of observed effects to specific interventions. This approach strengthens mechanistic de-risking and clarifies causal relationships in stroke pathology. Controlled variable manipulation is foundational for robust target validation.
What do quantitative MRI and behavioral measurements enable?
Quantitative MRI and behavioral assessments provide objective, reproducible endpoints for comparing lesion progression and functional deficits across experimental groups. These measurements enable precise evaluation of therapeutic efficacy and facilitate cross-study data integration. Quantitative outputs are critical for data-driven decision-making in preclinical R&D.
Why are replication requirements critical for MCAO cross-functional collaboration?
Replication of MCAO outcomes across teams ensures that findings are robust and not due to procedural variability or operator bias. Consistent replication supports cross-functional trust and enables reliable data sharing for portfolio decisions. Rigorous replication is key to advancing candidates with true translational potential.
What statistical analysis capabilities are needed before MCAO implementation?
Effective MCAO studies require statistical tools for analyzing lesion volume, behavioral scores, and blood flow data across groups and time points. Capabilities must include power analysis, variance assessment, and appropriate significance testing. Robust statistical infrastructure ensures that experimental conclusions are valid and actionable for R&D pipelines.
